Aug 21, 2013, 01.21 PM IST
Shares of Cadila Healthcare were today trading at Rs 654.50 per scrip in the afternoon trade on BSE, up 1.32 percent from its previous close.
Like this story, share it with millions of investors on M3
Zydus Cadila gets USFDFA nod to market anti-ulcer capsules
Shares of Cadila Healthcare were today trading at Rs 654.50 per scrip in the afternoon trade on BSE, up 1.32 percent from its previous close.
Like this story, share it with millions of investors on M3
Zydus Cadila gets USFDFA nod to market anti-ulcer capsules
Shares of Cadila Healthcare were today trading at Rs 654.50 per scrip in the afternoon trade on BSE, up 1.32 percent from its previous close.
Also read: Pharma cos seek customised insurance for legal settlements
"Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Lansoprazole delayed release (DR) Capsules in different strengths of 15 mg and 30 mg," Cadila Healthcare said in a filing to BSE.
The product had estimated sales of USD 501 million in 2012 as per the IMS Health data, it added.
"The group now has 81 approvals and has so far filed 186 abbreviated new drug applications (ANDAs) since the commencement of filing process in FY 2003-2004," Cadila Healthcare said.
Ahmedabad based firm has global operations spread across USA, Europe, Japan, Brazil, South Africa and 25 other emerging markets.
Shares of Cadila Healthcare were today trading at Rs 654.50 per scrip in the afternoon trade on BSE, up 1.32 percent from its previous close.
Anda sedang membaca artikel tentang
Zydus Cadila gets USFDFA nod to market anti-ulcer capsules
Dengan url
https://kesehatanda.blogspot.com/2013/08/zydus-cadila-gets-usfdfa-nod-to-market.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Zydus Cadila gets USFDFA nod to market anti-ulcer capsules
namun jangan lupa untuk meletakkan link
Zydus Cadila gets USFDFA nod to market anti-ulcer capsules
sebagai sumbernya
0 komentar:
Posting Komentar